Company Filing History:
Years Active: 2022
Title: Innovations by Samuel Kyeremateng in Pharmaceutical Compositions
Introduction
Samuel Kyeremateng is an accomplished inventor based in Mannheim, Germany. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of Hepatitis C Virus (HCV). His innovative work has led to the development of a unique solid pharmaceutical composition that showcases his expertise and dedication to improving healthcare.
Latest Patents
Samuel Kyeremateng holds a patent for solid pharmaceutical compositions aimed at treating HCV. The invention features a formulation that includes two key compounds. The first layer consists of 100 mg of Compound 1, combined with a pharmaceutically acceptable hydrophilic polymer and a surfactant, all formulated in an amorphous solid dispersion. The second layer contains 40 mg of Compound 2, along with similar excipients, also formulated in an amorphous solid dispersion. This innovative approach enhances the efficacy of the treatment.
Career Highlights
Samuel Kyeremateng is associated with AbbVie Inc., a leading global biopharmaceutical company. His work at AbbVie has allowed him to focus on developing advanced therapeutic solutions. His contributions have been instrumental in advancing the company's mission to provide innovative treatments for complex diseases.
Collaborations
Samuel has collaborated with notable colleagues, including Nancy E Sever and Ulrich Westedt. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Samuel Kyeremateng's work in developing solid pharmaceutical compositions for treating HCV exemplifies his commitment to innovation in the pharmaceutical industry. His contributions not only enhance treatment options but also reflect the importance of collaboration in advancing healthcare solutions.